Shionogi has borrowed ¥300bn from Sumitomo Mitsui Banking Corporation to pay for its purchase of US drugmaker IntraBio, and it intends to replace the loan with longer-term funding within a year. The company's notice says the bridge loan contract was signed and drawn on 10 November 2026.
The loan terms
The loan is unsecured. Interest is a base rate plus a spread, and the notice gives no spread figure. The final repayment date is 29 October 2027. Shionogi says it plans to refinance the loan into medium- to long-term funds before that deadline, without naming the instrument or the amount. The company says the effect on consolidated results for the year to March 2027 is minor.
The borrowing follows Shionogi's 5 October announcement that it would make IntraBio a wholly owned subsidiary (Earlier Tokyo Brief coverage). Interim statements filed with the bond shelf describe the plan as an acquisition of all IntraBio shares by Shionogi's US group company, Shionogi Inc..
Bond shelf as possible refinancing route
On the same day Shionogi filed a shelf registration with the Kanto Local Finance Bureau for up to ¥200bn of bonds. The registration is planned to take effect on 18 November and runs to 17 November 2028. The filing leaves the size, terms and underwriters of any issue undecided, and lists proceeds uses as capital spending, investments and loans, repaying borrowings and working capital. It does not link the shelf to IntraBio.
The interim statements also record a 29 October board resolution allowing up to ¥100bn of domestic unsecured bonds, issued between 1 December 2026 and 31 March 2027, with repayment of borrowings among the stated uses. Neither document says these bonds will take out the SMBC loan.
The interim statements show cash and equivalents of ¥376.5bn at 30 September, down from ¥711.4bn at the end of March. Shionogi said the statements had not been through auditor review.